Trial Profile
Clinical Trials Insight: 700027259
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Oct 2007
Price :
$35
*
At a glance
- Drugs Sparsentan (Primary) ; Irbesartan
- Indications Atherosclerosis; Atrial fibrillation; Diabetic nephropathies; Heart failure; Hypertension
- Focus Adverse reactions
- Sponsors Pharmacopeia
- 02 Oct 2007 New trial record.